Emiliem

Emiliem, Inc. is a private biotechnology company focused on understanding the molecular determinants of target modulation as it relates to therapeutic efficacy and potential drug adverse reactions. The company has a particular interest in diagnostic markers for rare diseases and computational methods for predicting positive and negative patient outcomes.